



## E.1 Surgical Valve Replacement

### E.1.1 DOAC versus VKA


**Figure 2: All-cause mortality at ≤12 months for DOAC versus VKA in biological surgical valve replacement**




**Figure 3: Major bleeding at ≤12 months for DOAC versus VKA in biological surgical valve replacement**




**Figure 4: Arterial thromboembolic events at ≤12 months for DOAC versus VKA in biological surgical valve replacement**



**Figure 5: Hospital re-admission at 12 months for DOAC versus VKA in biological surgical valve replacement**




**Figure 6: Thrombus on imaging at ≤12 months for DOAC versus VKA in biological surgical valve replacement**




## E.1.2 VKA versus SAPT


**Figure 7: All-cause mortality at ≤12 months for VKA versus SAPT in biological surgical valve replacement**




**Figure 8: Major bleeding at ≤12 months for VKA versus SAPT in biological surgical valve replacement**




**Figure 9: Arterial thromboembolic events at ≤12 months for VKA versus SAPT in biological surgical valve replacement**



**Figure 10: Hospital re-admission at 12 months for VKA versus SAPT in biological surgical valve replacement**



**Figure 11: Thrombus on imaging at ≤12 months for VKA versus SAPT in biological surgical valve replacement**



### E.1.3 VKA and SAPT versus VKA alone in surgical valve replacement

**Figure 12: Major systemic embolism or death from vascular causes at ≤12 months for VKA and SAPT versus VKA alone in biological surgical valve replacement**

